5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

 

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
I

ELEVATE TN Data on Acalabrutinib - Practice Changing Trial in CLL

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Ian W. Flinn
By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Ian W. Flinn
0 views
March 16, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
Hematologic Malignancies
06:39
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Frontline Therapy in CLL: Obinutuzumab + Ibrutinib, Ibrutinib vs. Ch…

Feat. I. Flinn
07:09
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

ELEVATE TN Data on Acalabrutinib - Practice Changing Trial in CLL

Feat. I. Flinn
11:47
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options for Newly Diagnosed Myeloma: Time to Incorporate C…

Feat. J. Berdeja
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among …

Feat. J. Berdeja
12:36
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Future Directions in Multiple Myeloma: Selinexor Approval, Venetocla…

Feat. J. Berdeja
18:23
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Time Limited Therapy in CLL, Ibrutinib vs Zanubrutinib in WM & L…

Feat. I. Flinn